A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
- Chronic Inflammatory Demyelinating Polyneuropathy
- CIDP
- CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- argenx
- Enrolment target
- 218
- Started
- 22 August 2025
- Main results due
- September 2027
- Study sites
- 101
- Registry updated
- 24 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021) * Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP * Has responded to IVIg in the past 5 years * Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g/kg * Has residual disability and active disease Exclusion Criteria: * Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes * Meets the criteria for possible or sensory CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021) * Use of other long-acting immunomodulatory treatment
What this study is about
In the sponsor’s own words, from the registry.
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).
More information can be found here: https://clinicaltrials.argenx.com/emvigorate
Study sites(101)
University of Alabama
Birmingham, Alabama, United States
Recruiting
Samir Macwan, M.D., Inc.
Rancho Mirage, California, United States
Recruiting
Colorado Springs Neurological Associates
Colorado Springs, Colorado, United States
Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
Recruiting
Homestead Associates in Research Inc
Homestead, Florida, United States
Recruiting
Visionary Investigators Network
Miami, Florida, United States
Recruiting
University of South Florida
Tampa, Florida, United States
Recruiting
Baptist Health Medical Group Neurology
Nicholasville, Kentucky, United States
Recruiting
Paradigm Health System
Slidell, Louisiana, United States
Recruiting
Erlanger Health System
Columbia, Maryland, United States
Recruiting
University of Michigan Hospital
Ann Arbor, Michigan, United States
Recruiting
University of Cincinnati Health
Cincinnati, Ohio, United States
Recruiting
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Recruiting
Jefferson Health Honickman Center
Philadelphia, Pennsylvania, United States
Recruiting
NeuroCarePlus
Houston, Texas, United States
Recruiting
National Neuromuscular Research Institute
Irving, Texas, United States
Recruiting
Instituto Privado Kremer
Córdoba, Argentina
Recruiting
INECO Neurociencias Oroño
Rosario, Argentina
Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia
Recruiting
Kepler Universitätsklinikum Linz - Med Campus III
Linz, Austria
Recruiting
Universitätsklinikum AKH Wien
Vienna, Austria
Recruiting
PSEG Centro de Pesquisa Clinica - Rua Borges Lagoa 1060
São Paulo, São Paulo, Brazil
Recruiting
PSEG Centro de Pesquisa Clinica
São Paulo, Brazil
Recruiting
University of Calgary
Calgary, Alberta, Canada
Recruiting
Black Tusk Research Group
Vancouver, British Columbia, Canada
Recruiting
Hospital Universitario San Ignacio
Bogotá, Colombia
Recruiting
Hospital Alma Máter de Antioquia
Medellín, Colombia
Recruiting
Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico
Medellín, Colombia
Recruiting
Fakultni nemocnice Brno
Brno, Czechia
Recruiting
Astra Kliinik
Tallinn, Estonia
Recruiting
Tartu University Hospital
Tartu, Estonia
Recruiting
AP-HM- Hôpital de La Timone
Marseille, Bouches-du-Rhone, France
Recruiting
AP-HP - Hôpital de la Pitié Salpétrière
Paris, Paris, France
Recruiting
CHU de Bordeaux - Hôpital Pellegrin
Bordeaux, France
Recruiting
AP-HP - Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Recruiting
CHU de Nice-Hôpital Pasteur
Nice, France
Recruiting
CHU de Strasbourg - Hôpital de Hautepierre
Strasbourg, France
Recruiting
CHU de Toulouse-Hôpital Pierre-Paul Riquet-Site de Purpan
Toulouse, France
Recruiting
Charité - Universitätsmedizin Berlin
Berlin, Germany
Recruiting
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Kiel, Germany
Recruiting
University General Hospital of Alexandroupolis
Athens, Greece
Recruiting
University General Hospital ''ATTIKON'' - General Hospital of West Attica H AGIA VARVARA
Chaïdári, Greece
Recruiting
Semmelweis Egyetem Genomikai Medicina és Ritka Betegségek Intézete
Budapest, Hungary
Recruiting
The Barzilai University Medical Center
Ashkelon, Israel
Recruiting
Hadassah Medical Center- Ein Kerem
Jerusalem, Israel
Recruiting
The Chaim Sheba Medical Center
Tel Litwinsky, Israel
Recruiting
AUSL di Bologna - Ospedale Bellaria
Bologna, Emilia-Romagna, Italy
Recruiting
AUSL di Bologna - Ospedale Bellaria
Bologna, Italy
Recruiting
Fondazione Istituto Neurologico Nazionale Casimiro Mondino IRCCS
Pavia, Italy
Recruiting
Azienda Ospedaliero-Universitaria Sant'Andrea
Roma, Italy
Recruiting
Fondazione PTV Policlinico Tor Vergata
Roma, Italy
Recruiting
Azienda Ospedaliero-Universitaria Policlinico Umberto I
Roma, Italy
Recruiting
IRCCS Istituto Clinico Humanitas
Rozzano, Italy
Recruiting
Aomori Prefectural Central Hospital
Aomori, Japan
Recruiting
Juntendo University Hospital
Bunkyō City, Japan
Recruiting
Chiba University Hospital
Chūōku, Japan
Recruiting
Seirei Hamamatsu Hospital
Hiroshima, Japan
Recruiting
Juntendo Shizuoka University Hospital
Izunokuni, Japan
Recruiting
Osaka Metropolitan University Hospital
Osaka, Japan
Recruiting
Saga University Hospital
Saga, Japan
Recruiting
Showing 60 of 101 sites — filter to narrow it down. 101 of the 101 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06920004. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me